Treatment-related toxicities in tumor-bearing cats treated with temozolomide alone or in combination with doxorubicin: a pilot assessment

Simple item page
dc.contributor.authorGagnon, Jeromeen
dc.contributor.authorDervisis, Nikolaos G.en
dc.contributor.authorKitchell, Barbara E.en
dc.date.accessioned2016-11-15T20:49:13Zen
dc.date.available2016-11-15T20:49:13Zen
dc.date.issued2012-08-01en
dc.description.abstractA retrospective study assessing treatment-related toxicities in tumor-bearing cats treated with temozolomide (TMZ) alone or in combination with doxorubicin was conducted. TMZ was administered orally once a day for 5 days every 3 weeks at a dose of 20 mg/cat. Tumor response was evaluated with standard World Health Organization criteria and toxicity was monitored using veterinary co-operative oncology group–common terminology criteria for adverse events (VCOG—CTCAE) criteria. Ten tumor-bearing cats with various types of malignancies were treated with TMZbased chemotherapy. Eight cats were evaluable for response. Two cats achieved a complete response, one achieved stable disease and five achieved a partial response. Four grade III and one grade IV hematological toxicities, and one grade IV gastrointestinal toxicity were observed. Four cats were euthanased as a result of apparent toxicity. One cat was euthanased as a result of severe and prolonged myelosuppression with fever. Three were euthanased for grade III pleural and pericardial effusions. Effusion was seen in cats treated with higher cumulative dose of TMZ (P = 0.0046). Planned additional case accrual was discontinued because of unacceptable levels of toxicity despite evidence of efficacy in some of the cats. Additional investigation is needed to elucidate this unexpected apparent cumulative toxicity.en
dc.description.versionPublished versionen
dc.format.extent560 - 565 (6) page(s)en
dc.format.mimetypeapplication/pdfen
dc.identifier.doihttps://doi.org/10.1177/1098612X12445146en
dc.identifier.issn1098-612Xen
dc.identifier.issue8en
dc.identifier.urihttp://hdl.handle.net/10919/73456en
dc.identifier.volume14en
dc.language.isoenen
dc.publisherSAGEen
dc.relation.urihttp://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000312554000008&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=930d57c9ac61a043676db62af60056c1en
dc.rightsIn Copyrighten
dc.rights.urihttp://rightsstatements.org/vocab/InC/1.0/en
dc.subjectVeterinary Sciencesen
dc.subjectPHASE-I TRIALen
dc.subjectDOGSen
dc.subjectCHEMOTHERAPYen
dc.subjectLYMPHOMAen
dc.subjectCYCLOPHOSPHAMIDEen
dc.subject5-FLUOROURACILen
dc.subjectDACARBAZINEen
dc.subjectIFOSFAMIDEen
dc.subjectLOMUSTINEen
dc.subjectEFFICACYen
dc.titleTreatment-related toxicities in tumor-bearing cats treated with temozolomide alone or in combination with doxorubicin: a pilot assessmenten
dc.title.serialJournal of Feline Medicine and Surgeryen
dc.typeArticle - Refereeden
dc.type.dcmitypeTexten
pubs.organisational-group/Virginia Techen
pubs.organisational-group/Virginia Tech/All T&R Facultyen
pubs.organisational-group/Virginia Tech/Faculty of Health Sciencesen
pubs.organisational-group/Virginia Tech/Veterinary Medicineen
pubs.organisational-group/Virginia Tech/Veterinary Medicine/CVM T&R Facultyen
pubs.organisational-group/Virginia Tech/Veterinary Medicine/Small Animal Clinical Sciencesen

Files

Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
Treatment-related toxicities in tumor-bearing cats treated with temozolomide alone or in combination with doxorubicin.pdf
Size:
748.17 KB
Format:
Adobe Portable Document Format
Description:
Publisher's Version
Download
License bundle
Now showing 1 - 1 of 1
Name:
VTUL_Distribution_License_2016_05_09.pdf
Size:
18.09 KB
Format:
Adobe Portable Document Format
Description:
Download

Collections

All Faculty Deposits
Scholarly Works, Small Animal Clinical Sciences